Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RenovoRx Inc. Common Stock
RNXT | US
1.02
USD-0.01
-0.97%
RNXT | US
About RenovoRx Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
15/04/2026
Close
1.02
Open
0.98
High
1.03
Low
0.98
RenovoRx Inc. a clinical-stage biopharmaceutical company focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos California.
View LessRNXT | US
Risk
86.9
Sharpe
0.34
Luna's Score
45/100
Recommendation
Sell
Luna says (RNXT | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
53.8%1 month
86.9%3 months
68.7%6 months
87.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.59
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-4.72
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-11.39M
MarketCap
24.47M
MarketCap(USD)
24.47M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-155.12
Short ratio
2.30
Short perc.
0.49
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.22
Range1M
0.47
Range3M
0.53
Volumes: Market Activity
Rel. volume
0.46
Price X volume
225.85K
